Stockreport

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]

Vanda Pharmaceuticals Inc.  (VNDA) 
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm Check Earnings Report
PDF Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 rec [Read more]